Literature DB >> 11522619

Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.

M Kitazono1, M E Goldsmith, T Aikou, S Bates, T Fojo.   

Abstract

The presence of coxsackie and adenovirus receptor (CAR) and alpha(v) integrin on cell surfaces is required for efficient adenovirus infection. Treatment of cells with the histone deacetylase inhibitor FR901228 (depsipeptide) increased CAR and alpha(v) integrin RNA levels in six cancer cell lines. Sodium butyrate and trichostatin A, other histone deacetylase inhibitors, caused similar increases. Cells treated with FR901228 prior to infection had a 4-10-fold increase in transgene expression from a beta-galactosidase-expressing adenoviral vector. These studies suggest that FR901228 increases the efficiency of adenoviral transgene expression and may be useful in cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522619

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Long-term engraftment of multipotent mesenchymal stromal cells that differentiate to form myogenic cells in dogs with Duchenne muscular dystrophy.

Authors:  Yuko Nitahara-Kasahara; Hiromi Hayashita-Kinoh; Sachiko Ohshima-Hosoyama; Hironori Okada; Michiko Wada-Maeda; Akinori Nakamura; Takashi Okada; Shin'ichi Takeda
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors.

Authors:  Anne Keriel; Céline René; Chad Galer; Joseph Zabner; Eric J Kremer
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  The HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replication.

Authors:  Angelika Danielsson; Helena Dzojic; Victoria Rashkova; Wing-Shing Cheng; Magnus Essand
Journal:  PLoS One       Date:  2011-02-17       Impact factor: 3.240

Review 4.  Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription.

Authors:  Hiroshi Uchida; Tetsuo Maruyama; Toru Arase; Masanori Ono; Takashi Nagashima; Hirotaka Masuda; Hironori Asada; Yasunori Yoshimura
Journal:  Reprod Med Biol       Date:  2005-05-03

5.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

6.  Isoform-specific regulation and localization of the coxsackie and adenovirus receptor in human airway epithelia.

Authors:  Katherine J D A Excoffon; Nicholas D Gansemer; Matthew E Mobily; Philip H Karp; Kalpaj R Parekh; Joseph Zabner
Journal:  PLoS One       Date:  2010-03-26       Impact factor: 3.240

Review 7.  TRAIL gene therapy: from preclinical development to clinical application.

Authors:  Thomas S Griffith; Brittany Stokes; Tamara A Kucaba; James K Earel; Rebecca L VanOosten; Erik L Brincks; Lyse A Norian
Journal:  Curr Gene Ther       Date:  2009-02       Impact factor: 4.391

8.  Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor.

Authors:  E M Lee; S H Hong; Y J Lee; Y H Kang; K C Choi; S H Choi; I H Kim; S J Lim
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-16       Impact factor: 4.553

9.  Histone deacetylase inhibition enhances adenoviral vector transduction in inner ear tissue.

Authors:  A Taura; K Taura; Y H Choung; M Masuda; K Pak; E Chavez; A F Ryan
Journal:  Neuroscience       Date:  2010-01-06       Impact factor: 3.590

10.  Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336).

Authors:  Robert P Whitehead; Cathryn Rankin; Paulo M G Hoff; Philip J Gold; Kevin G Billingsley; Robert A Chapman; Lucas Wong; John H Ward; James L Abbruzzese; Charles D Blanke
Journal:  Invest New Drugs       Date:  2008-10-22       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.